132 related articles for article (PubMed ID: 26004420)
1. Inhibitors of the renal outer medullary potassium channel: a patent review.
Martelli A; Testai L; Breschi MC; Calderone V
Expert Opin Ther Pat; 2015; 25(9):1035-51. PubMed ID: 26004420
[TBL] [Abstract][Full Text] [Related]
2. The Renal Outer Medullary Potassium Channel (ROMK): An Intriguing Pharmacological Target for an Innovative Class of Diuretic Drugs.
Calderone V; Martelli A; Piragine E; Citi V; Testai L; Breschi MC
Curr Med Chem; 2018; 25(23):2627-2636. PubMed ID: 29022503
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic inhibition of the renal outer medullary potassium channel causes diuresis and natriuresis in the absence of kaliuresis.
Garcia ML; Priest BT; Alonso-Galicia M; Zhou X; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Liu J; Swensen A; Pai LY; Xiao J; Hernandez M; Hoagland K; Owens K; Tang H; de Jesus RK; Roy S; Kaczorowski GJ; Pasternak A
J Pharmacol Exp Ther; 2014 Jan; 348(1):153-64. PubMed ID: 24142912
[TBL] [Abstract][Full Text] [Related]
4. Diuretic complications.
Greenberg A
Am J Med Sci; 2000 Jan; 319(1):10-24. PubMed ID: 10653441
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics.
Aretz CD; Vadukoot AK; Hopkins CR
J Med Chem; 2019 Oct; 62(19):8682-8694. PubMed ID: 31034224
[TBL] [Abstract][Full Text] [Related]
6. The Renal Outer Medullary Potassium Channel Inhibitor, MK-7145, Lowers Blood Pressure, and Manifests Features of Bartter's Syndrome Type II Phenotype.
Hampton C; Zhou X; Priest BT; Pai LY; Felix JP; Thomas-Fowlkes B; Liu J; Kohler M; Xiao J; Corona A; Price O; Gill C; Shah K; Rasa C; Tong V; Owens K; Ormes J; Tang H; Roy S; Sullivan KA; Metzger JM; Alonso-Galicia M; Kaczorowski GJ; Pasternak A; Garcia ML
J Pharmacol Exp Ther; 2016 Oct; 359(1):194-206. PubMed ID: 27432892
[TBL] [Abstract][Full Text] [Related]
7. Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic.
Jiang J; Ding FX; Zhou X; Bateman TJ; Dong S; Gu X; Keh deJesus R; Pio B; Tang H; Chobanian HR; Levorse D; Hu M; Thomas-Fowlkes B; Margulis M; Koehler M; Weinglass A; Gibson J; Houle K; Yudkovitz J; Hampton C; Pai LY; Samuel K; Cutarelli T; Sullivan K; Parmee ER; Davies I; Pasternak A
J Med Chem; 2021 Jun; 64(11):7691-7701. PubMed ID: 34038119
[TBL] [Abstract][Full Text] [Related]
8. Targeting the inward-rectifier potassium channel ROMK in cardiovascular disease.
Garcia ML; Kaczorowski GJ
Curr Opin Pharmacol; 2014 Apr; 15():1-6. PubMed ID: 24721647
[TBL] [Abstract][Full Text] [Related]
9. The design and synthesis of novel spirocyclic heterocyclic sulfone ROMK inhibitors as diuretics.
Chobanian HR; Guo Y; Pio B; Tang H; Teumelsan N; Clements M; Frie J; Ferguson R; Guo Z; Thomas-Fowlkes BS; Felix JP; Liu J; Kohler M; Priest B; Hampton C; Pai LY; Corona A; Metzger J; Tong V; Joshi EM; Xu L; Owens K; Maloney K; Sullivan K; Pasternak A
Bioorg Med Chem Lett; 2017 Feb; 27(4):1109-1114. PubMed ID: 28111141
[TBL] [Abstract][Full Text] [Related]
10. Discovery of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor for the Treatment of Heart Failure.
Richter JM; Gunaga P; Yadav N; Bora RO; Bhide R; Rajugowda N; Govindrajulu K; Godesi S; Akuthota N; Rao P; Sivaraman A; Panda M; Kaspady M; Gupta A; Mathur A; Levesque PC; Gulia J; Dokania M; Ramarao M; Kole P; Chacko S; Lentz KA; Sivaprasad Lvj S; Thatipamula RP; Sridhar S; Kamble S; Govindrajan A; Soleman SI; Gordon DA; Wexler RR; Priestley ES
J Med Chem; 2024 Jun; 67(11):9731-9744. PubMed ID: 38807539
[TBL] [Abstract][Full Text] [Related]
11. The inwardly rectifying potassium channel Kir1.1: development of functional assays to identify and characterize channel inhibitors.
Felix JP; Priest BT; Solly K; Bailey T; Brochu RM; Liu CJ; Kohler MG; Kiss L; Alonso-Galicia M; Tang H; Pasternak A; Kaczorowski GJ; Garcia ML
Assay Drug Dev Technol; 2012 Oct; 10(5):417-31. PubMed ID: 22881347
[TBL] [Abstract][Full Text] [Related]
12. Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds.
Sarafidis PA; Georgianos PI; Lasaridis AN
Expert Opin Drug Saf; 2010 Mar; 9(2):243-57. PubMed ID: 20095917
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of targeting the K
Priest BT; Pasternak A
Future Med Chem; 2017 Oct; 9(16):1963-1977. PubMed ID: 29076349
[TBL] [Abstract][Full Text] [Related]
14. Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores.
Dong S; VanGelder K; Shi ZC; Yu Y; Wu Z; Ferguson R; Guo ZZ; Tang H; Frie J; Fu Q; Gu X; Priest BT; Thomas-Fowlkes B; Weinglass A; Margulis M; Liu J; Pai LY; Hampton C; Haimbach RE; Owens K; Tong V; Xu S; Hu M; Zingaro GJ; Morissette P; Ehrhart J; Roy S; Sullivan K; Pasternak A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2559-2566. PubMed ID: 28431879
[TBL] [Abstract][Full Text] [Related]
15. Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel.
Bhave G; Chauder BA; Liu W; Dawson ES; Kadakia R; Nguyen TT; Lewis LM; Meiler J; Weaver CD; Satlin LM; Lindsley CW; Denton JS
Mol Pharmacol; 2011 Jan; 79(1):42-50. PubMed ID: 20926757
[TBL] [Abstract][Full Text] [Related]
16. New onset diabetes during antihypertensive therapy.
Alderman MH
Am J Hypertens; 2008 May; 21(5):493-9. PubMed ID: 18437139
[TBL] [Abstract][Full Text] [Related]
17. The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation.
Ng CF; Koon CM; Cheung DW; Lam MY; Leung PC; Lau CB; Fung KP
J Ethnopharmacol; 2011 Oct; 137(3):1366-72. PubMed ID: 21855622
[TBL] [Abstract][Full Text] [Related]
18. Update of diuretics in the treatment of hypertension.
Padilla MC; Armas-Hernández MJ; Hernández RH; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):154-60. PubMed ID: 17414583
[TBL] [Abstract][Full Text] [Related]
19. Treating essential hypertension. The first choice is usually a thiazide diuretic.
Prescrire Int; 2014 Sep; 23(152):215-20. PubMed ID: 25325125
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.
Tang H; de Jesus RK; Walsh SP; Zhu Y; Yan Y; Priest BT; Swensen AM; Alonso-Galicia M; Felix JP; Brochu RM; Bailey T; Thomas-Fowlkes B; Zhou X; Pai LY; Hampton C; Hernandez M; Owens K; Roy S; Kaczorowski GJ; Yang L; Garcia ML; Pasternak A
Bioorg Med Chem Lett; 2013 Nov; 23(21):5829-32. PubMed ID: 24075732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
